| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Irloxacin targets bacterial DNA gyrase and topoisomerase IV, the classic targets of fluoroquinolone antibiotics. These enzymes are essential for bacterial DNA replication, transcription, and repair. Inhibition of these enzymes leads to DNA damage and bacterial cell death. The compound’s enhanced activity at acidic pH is driven by its distinct C7 pyrrol-1-yl substituent.
|
|---|---|
| ln Vitro |
In vitro, Irloxacin has a broad antimicrobial spectrum against both Gram-positive and Gram-negative bacteria. It shows enhanced activity under acidic pH conditions, which is critical for studies in phagolysosomes and M. avium models. The MIC range against Staphylococcus is 0.06-1 mg/L, and the MIC50 against M. tuberculosis is 8 µg/mL. Oral bioavailability has been confirmed in preclinical studies.
|
| ln Vivo |
In vivo, Irloxacin is orally active and has been studied in preclinical models. The NOAEL in Beagle dogs is 10 mg/kg/day in a 29-week oral study. It is being studied to combat bacterial resistance and improve infection control strategies.
|
| Enzyme Assay |
The in vitro antimicrobial susceptibility assay for Irloxacin involves determining the minimum inhibitory concentration (MIC) against various bacterial strains. The compound’s activity is tested at different pH levels to demonstrate its pH-dependent potency. The MIC50 against M. tuberculosis is determined using standard broth microdilution methods.
|
| Cell Assay |
In vitro cell-based assays for Irloxacin are not standard, as it is an antibacterial agent. However, its activity against intracellular bacteria may be assessed in infected cell cultures.
|
| Animal Protocol |
In vivo animal studies for Irloxacin would involve infection models in rodents or other animals. The compound would be administered orally or by injection, and bacterial load in tissues would be measured. The NOAEL of 10 mg/kg/day in Beagle dogs supports translational toxicology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Irloxacin are not detailed in the provided literature. It is known to be orally bioavailable. The compound shows pH-dependent activity.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for Irloxacin are available in the provided literature, aside from the NOAEL of 10 mg/kg/day in Beagle dogs. The compound is for research use only.
|
| Additional Infomation |
Irloxacin is a fluoroquinolone antibiotic with pH-dependent activity. It has a broad antimicrobial spectrum. It is orally active. It is for research use only. Its CAS number is 91524-15-1.
|
| Molecular Formula |
C16H13FN2O3
|
|---|---|
| Molecular Weight |
300.28400
|
| Exact Mass |
300.091
|
| Elemental Analysis |
C, 64.00; H, 4.36; F, 6.33; N, 9.33; O, 15.98
|
| CAS # |
91524-15-1
|
| Related CAS # |
122949-49-9 (sodium);91524-15-1 (free acid);
|
| PubChem CID |
65828
|
| Appearance |
Solid powder
|
| Density |
1.36g/cm3
|
| Boiling Point |
495.9ºC at 760mmHg
|
| Flash Point |
253.7ºC
|
| Index of Refraction |
1.634
|
| LogP |
2.649
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
502
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C(=O)C2C(=CC(N3C=CC=C3)=C(C=2)F)N(CC)C=1)O
|
| InChi Key |
RZLHGQLYNZQZQQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H13FN2O3/c1-2-18-9-11(16(21)22)15(20)10-7-12(17)14(8-13(10)18)19-5-3-4-6-19/h3-9H,2H2,1H3,(H,21,22)
|
| Chemical Name |
1-ethyl-6-fluoro-4-oxo-7-pyrrol-1-ylquinoline-3-carboxylic acid
|
| Synonyms |
E 3432; E3432; E-3432; Irloxacin; Pirfloxacin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~111.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3302 mL | 16.6511 mL | 33.3023 mL | |
| 5 mM | 0.6660 mL | 3.3302 mL | 6.6605 mL | |
| 10 mM | 0.3330 mL | 1.6651 mL | 3.3302 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
